Utility of Follow-up Dopamine Transporter SPECT With 123I-FP-CIT in the Diagnostic Workup of Patients With Clinically Uncertain Parkinsonian Syndrome

2017 ◽  
Vol 42 (8) ◽  
pp. 589-594 ◽  
Author(s):  
Ivayla Apostolova ◽  
Daulat S. Taleb ◽  
Axel Lipp ◽  
Imke Galazky ◽  
Dennis Kupitz ◽  
...  
2014 ◽  
Vol 152 (2-3) ◽  
pp. 344-349 ◽  
Author(s):  
Michele Tinazzi ◽  
Francesca Morgante ◽  
Angela Matinella ◽  
Tommaso Bovi ◽  
Antonino Cannas ◽  
...  

2013 ◽  
pp. 20-24
Author(s):  
Generoso Uomo ◽  
Simona Miraglia ◽  
Pier Giorgio Rabitti

BACKGROUND Almost all patients presenting with chronic hyperamylasemia undergo an expensive, long, difficult and often repeated diagnostic workup even if this occurrence is not associated with symptoms or with known pancreatotoxic factors. This is in relationship with the poor knowledge that, beside hyperenzymemia secondary to pancreatic diseases and systemic illnesses, various non-pathological forms of chronic hyperamylasemia can occur in clinical practice. AIM OF THE STUDY This study was addressed to assess the clinical characteristics of patients presenting with chronic hyperamylasemia unrelated to pancreatic diseases (CHUPD). PATIENTS AND METHODS Data of all patients with CHUPD were retrospectively reviewed (June 1997-March 2007). Forty patients were included in the study; median follow- up was 33 months (range 3-84 months). CHUPD was secondary to: a) chronic benign pancreatic hyperamylasemia, 16 patients (40%); b) macroamylasemia, 15 patients (37.5%); c) salivary hyperamylasemia, 9 patients (22.5%). Gilbert’s syndrome was present in 13 patients (32.5%; 8 with macroamylasemia) and hyperdyslipidemia in 8 patients (20%; 5 with chronic benign pancreatic hyperamylasemia). Diagnostic exams (all in the normal range) performed before our observation were: Ca19-9 serum level in 37/40 (92.5%), ultrasonography and computed tomography-scan in all patients, endoscopic retrograde cholangiopancreatography in 21/40 (52.5%), abdominal magnetic resonance in 14/40 (35%). Previous diagnosis in these asymptomatic subjects were: chronic pancreatitis in 26 cases (65%); recurrent pancreatitis in 10 cases (25%); the remaining 4 patients (10%) were addressed without a specific diagnosis. CONCLUSIONS In clinical practice, the occurrence of an unexplained chronic hyperamylasemia very often allows to an unappropriate diagnostic workup due to the poor familiarity with CHUPD conditions.


2008 ◽  
Vol 441 (3) ◽  
pp. 291-295 ◽  
Author(s):  
Soili M. Lehto ◽  
Tommi Tolmunen ◽  
Jyrki Kuikka ◽  
Minna Valkonen-Korhonen ◽  
Mikko Joensuu ◽  
...  

1999 ◽  
Vol 246 (4) ◽  
pp. 283-286 ◽  
Author(s):  
N. Soonawala ◽  
K. P. Bhatia ◽  
J. H. M. Yeung ◽  
N. P. Quinn ◽  
C. D. Marsden

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
S. R. Suwijn ◽  
H. W. Berendse ◽  
C. V. M. Verschuur ◽  
R. M. A. de Bie ◽  
J. Booij

Background. Differentiating Parkinson’s disease (PD) from multiple system atrophy (MSA) can be challenging especially early in the course of the disease. Previous studies have shown that midbrain serotonin transporter (SERT) availability in patients with established MSA was significantly lower compared to PD. It is unknown if this is also true for early-stage patients. Methods. 77 early-stage, untreated PD patients were recruited between 1995 and 1998, underwent [123I]β-CIT SPECT imaging, and were followed for at least five years. 16 patients were lost to followup, and in 4 the diagnosis was changed to another atypical parkinsonian syndrome, but not in MSA. In 50 patients, the PD diagnosis was unchanged at followup. In seven patients, the diagnosis was changed to MSA at followup. We retrospectively assessed baseline midbrain SERT availability as well as midbrain SERT-to-striatal dopamine transporter (DAT) ratios. Results. No difference in baseline [123I]β-CIT SERT availability was found. The midbrain SERT-to-striatal DAT ratio for whole striatum was significantly lower in patients with PD compared to MSA (P=0.049). However, when adjusting for the disease duration at imaging this difference is not significant (P=0.070). Conclusion. Midbrain SERT availability is not different between early-stage PD and MSA. Therefore, SERT imaging is not useful to differentiate between early PD and MSA.


Allergy ◽  
2017 ◽  
Vol 72 (12) ◽  
pp. 1944-1952 ◽  
Author(s):  
A. Ruiz Oropeza ◽  
C. Bindslev-Jensen ◽  
S. Broesby-Olsen ◽  
T. Kristensen ◽  
M. B. Møller ◽  
...  

2006 ◽  
Vol 27 (12) ◽  
pp. 933-937 ◽  
Author(s):  
Vicky L. Marshall ◽  
Jim Patterson ◽  
Donald M. Hadley ◽  
Katherine A. Grosset ◽  
Donald G. Grosset

Sign in / Sign up

Export Citation Format

Share Document